复方樟柳碱注射液治疗缺血性眼病综述

介绍复方樟柳碱（compound anisodine，cA）的组成、特殊历史背景和处方依据及过敏试验；同时介绍对比分析复方樟柳碱和妥拉苏林治疗眼缺血的机制研究。实验结果提示：CA治疗眼缺血使脉络膜TXB2、6-Keto-PGF1α、VIP、ir-ET等维持正常水平，降低自由基、cAMP并使cGMP保持高水平，改善脉络膜血管运动功能，增加血流量；抑制炎症、抑制纤维增生；促进出血、水肿、渗出及机化的吸收。临床验证共403例原发性和继发性缺血性视神经、视网膜、脉络膜病变，对照组和治疗组各112例，开放组179例。对照组用妥拉苏林（TZL）注射液，治疗组及开放组用CA注射液，疗程21d。治疗组有效率82，14％，对照组为36．61％，二者比较差异有统计学意义，开放组有效率为80．45％。结果：CA注射液对治疗原发及继发缺血性视神经、视网膜脉络膜病变是有效和安全的并优于扩血管药TZL。

About composition, special historical background, evidence of prescription and allergic test of compound anisodine, CA were introduced. Meanwhile 7 animal experiments for study the mechanism in treating ocular ischemia with CA. The results indicated that CA is improving vasomotor function of choroid; Promoting absorption of tissue edema, exudate and hemorrhage; Inhibiting inflammation and fibrin-proliferation. In addition, CA relieves ischemic pain, regulates blood pressure and pulse to normal, improves sleep, increases visual acuity in Clinical practice. The 403cases in IT stage clinical certification were pointed out that CA in treating ocular ischemia was effective and safe and much better than tolazolin, TZL.